In vivo reactivation of DNases in implanted human prostate tumors after administration of a vitamin C/K-3 combination

In vivo reactivation of DNases in implanted human prostate tumors after administration of a vitamin C/K-3 combination

Taper H S; Jamison J M; Gilloteaux J; Gwin C A; Gordon T; Summers J L

Journal of Histochemistry & Cytochemistry

2001

2001-01

Human prostate cancer cells (DU145) implanted into nude mice are deficient in DNase activity. After administration of a vitamin C/vitamin K-3 combination, both alkaline DNase (DNase I) and acid DNase (DNase II) activities were detected in cryosections with a histochemical lead nitrate technique. Alkaline DNase activity appeared 1 hr after vitamin administration, decreased slightly until 2 hr, and disappeared by 8 hr after treatment. Acid DNase activity appeared 2 hr after vitamin administration, reached its highest levels between 4 and 8 hr, and maintained its activity 24 hr after treatment. Methyl green staining indicated that DNase expression was accompanied by a decrease in DNA content of the tumor cells. Microscopic examination of 1-mum sections of the tumors indicated that DNase reactivation and the subsequent degradation of DNA induced multiple forms of tumor cell death, including apoptosis and necrosis. The primary form of vitamin-induced tumor cell death was autoschizis, which is characterized by membrane damage and the progressive loss of cytoplasm through a series of self-excisions. These self-excisions typically continue until the perikaryon consists of an apparently intact nucleus surrounded by a thin rim of cytoplasm that contains damaged organelles.

apoptosis; cancer; cancer-chemotherapy; carcinoma cells; Cell Biology; cell death; deoxyribonuclease-ii; DNASE; growth-invitro; identification; lines; necrobiology; pretreatment; programmed cell-death; Prostate cancer; synergistic antitumor-activity; vitamin C; vitamin K-3

Journal Article

Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).

109-119

1

49